About 40% of EGPA patients have perinuclear ANCA antibodies against myeloperoxidase (MPO), resulting in the classification of EGPA as an ANCA-associated vasculitis (192, 193). This evidence concerns the gene MPO and anti-neutrophil cytoplasmic antibody-associated vasculitis.